What's hot

View all perspectives
      Abstract 2503: Clofutriben (HSD-1 inhibitor) minimizes adrenal suppression. Adding clofutriben to prednisolone boosts A

      Akhil Sood MD AkhilSoodMD

      9 months 3 weeks ago
      Abstract 2503: Clofutriben (HSD-1 inhibitor) minimizes adrenal suppression. Adding clofutriben to prednisolone boosts ACTH & cortisol levels with fewer patients with suppressed morning cortisol (≤5.0 mg/dL) (34% vs 14%). @RheumNow #ACR24 #GCTox
      Biosimilar switching in practice

      Hyrich: UK experience
      Switching to biosimilar has no immediate benefit to patients but

      Eric Dein ericdeinmd

      9 months 3 weeks ago
      Biosimilar switching in practice Hyrich: UK experience Switching to biosimilar has no immediate benefit to patients but saves NHS money Allows for gain share that can be re-invested in pt care Transparency in switching in explaining to pts and offering resource @RheumNow #ACR24
      Abstract 1876: Developed a machine learning model w/ #SDoH covariates to accurately identify patients with SLE and ESR

      Akhil Sood MD AkhilSoodMD

      9 months 3 weeks ago
      Abstract 1876: Developed a machine learning model w/ #SDoH covariates to accurately identify patients with SLE and ESRD in NIH All of US dataset @RheumNow #ACR24 https://t.co/TLDSiBZZPs
      Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over t

      Antoni Chan MD (Prof) synovialjoints

      9 months 3 weeks ago
      Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over the long term. Key findings: - AxSpA: 3.7% incidence (1.3/100 PY) with BKZ. - PsA: Only 0.2% incidence (0.1/100 PY). - All events were mild/moderate, with no… https://t.co/jkUwHJk3FJ https://t.co/gTcCzeC88e
      If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options

      Brian Jaros, MD Dr_Brian_MD

      9 months 3 weeks ago
      If you’re starting with DMARD (according to ACR/VF guidelines) tx in TAK - MTX and AZA are probably equivalent options… MMF not so much @RheumNow #ACR24 https://t.co/jn52ujtspo
      Hyrich:
      ETN originator vs biosimilar initiation
      - DAS28 - no signif change at B/L, 6mo, 12 mo.

      Switch?
      Matched pts in E

      Eric Dein ericdeinmd

      9 months 3 weeks ago
      Hyrich: ETN originator vs biosimilar initiation - DAS28 - no signif change at B/L, 6mo, 12 mo. Switch? Matched pts in ETN switch v cont originator - good b/l control on Rx -DAS28 maintained w switch 10% did go back to originator, felt less good tho similar DAS #ACR24 @RheumNow https://t.co/RHRit5CtUu
      Food for thought 🤔

      Abstract 1900 found non-diet soda and certain supplements (folate, B-vitamins, fish oil) were hig

      Akhil Sood MD AkhilSoodMD

      9 months 3 weeks ago
      Food for thought 🤔 Abstract 1900 found non-diet soda and certain supplements (folate, B-vitamins, fish oil) were higher among individuals with incident SpA compared to controls @RheumNow #ACR24 https://t.co/qUXcxSfTxE
      Older adults with late-onset RA (LORA) with more erosive changes, even with DMARD use

      But is T2T met?
      LORA with higher

      Jiha Lee JihaRheum

      9 months 3 weeks ago
      Older adults with late-onset RA (LORA) with more erosive changes, even with DMARD use But is T2T met? LORA with higher DAS on diagnosis and yet 10% on bDMARD vs 26% of young-onset RA #ACR24 @RheumNow ABST#2224 https://t.co/dYs1JwcJeq
      Early observational data suggesting JAK inhibitors can play a role in TAK tx

      We have seen this with UPA in GCA this con

      Brian Jaros, MD Dr_Brian_MD

      9 months 3 weeks ago
      Early observational data suggesting JAK inhibitors can play a role in TAK tx We have seen this with UPA in GCA this conference… time for SELECT-TAK ! @RheumNow #ACR24 https://t.co/B2Wa8sOFTp
      Abstract 1912: Time to close the gaps in #PsA care
      RISE Registry reveals:
      - higher disease activity in the South
      - mor

      Akhil Sood MD AkhilSoodMD

      9 months 3 weeks ago
      Abstract 1912: Time to close the gaps in #PsA care RISE Registry reveals: - higher disease activity in the South - more oral steroids + csDMARDs, fewer bDMARDs, and more comorbidities in the Midwest @RheumNow #ACR24
      Provocative study suggests SLE has changed. Big picture: less physical manifestations, more serologic

      @andreafava why i

      Mike Putman EBRheum

      9 months 3 weeks ago
      Provocative study suggests SLE has changed. Big picture: less physical manifestations, more serologic @andreafava why isn't this just more-testing & more-sensitive testing shifting the phenotype of who we diagnose? #ACR24 @RheumNow Abstr#2413 https://t.co/o2e9TFMsUp
      Lots of data on TYKs including much supporting efficacy in interferon inhibition

      Can we really call interferon signalli

      Mike Putman EBRheum

      9 months 3 weeks ago
      Lots of data on TYKs including much supporting efficacy in interferon inhibition Can we really call interferon signalling a "central" pathway in SLE? Inhibiting it has been modestly successful, at best, and mostly for skin dx #ACR24 @RheumNow Abstr#2434 https://t.co/Q94FQz3gzO
      #2222
      📊 New data on #RA-ILD:

      🔴In early RA, ILD prevalence hits 21.4% after 10 years, with 8.2% cumulative incide

      Caoilfhionn Connolly CaoilfhionnMD

      9 months 3 weeks ago
      #2222 📊 New data on #RA-ILD: 🔴In early RA, ILD prevalence hits 21.4% after 10 years, with 8.2% cumulative incidence at 5 years (IR 14.9/1000 PY). 🔴ILD often precedes or coincides with RA onset. 🔴NSIP > UIP 🔴airway involvement less common than expected. #acr24 @RheumNow
      Using longitudinal claims data, this study explores the safety of non-conventional combination targeted therapy in adult

      Antoni Chan MD (Prof) synovialjoints

      9 months 3 weeks ago
      Using longitudinal claims data, this study explores the safety of non-conventional combination targeted therapy in adults with psoriatic arthritis (PsA). Key findings: - 42,821 PsA patients analyzed; only 1.1% on combination therapy. - Increased risk of serious infections:… https://t.co/Jghmz9lkLd https://t.co/YqwJlTKcEi
      RA patients affected by frailty at a younger age
      in @VARA frailty associated with lower BMD
      But frailty is modifiable!

      Jiha Lee JihaRheum

      9 months 3 weeks ago
      RA patients affected by frailty at a younger age in @VARA frailty associated with lower BMD But frailty is modifiable! #GeriRheum #ACR24 @RheumNow ABST#2140 https://t.co/BoTGoESB43
      How well do you know this week's rheumatology news?
      Take the rheumIQ quiz
      Take the RheumIQ Quiz

      Podcasts

      • ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
      • ACR24 JAK TYK Topic Panel
      • RheumNow Day 1 Recap ACR Convergence 2024 Highlights

      Catch up on Conference Podcasts

      ×